Center-Authored Papers

Filters: Author is Redman, Mary W  [Clear All Filters]
Journal Article
Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC.  2014.  Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications.. Clinical lung cancer. 15(1) Abstract
Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW.  2012.  Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity.. Clinical lung cancer.
McGregor BA, Dolan ED, Murphy KM, Sannes TS, Highland KB, Albano DL, Ward AA, Charbonneau AM, Redman MW, Ceballos RM.  2015.  Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention.. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. Abstract
Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, Goulart B, Lee S, Santana-Davila R, Liao J et al..  2016.  Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.. Head & neck. Abstract
Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR.  2012.  Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley J, Gandara DR.  2008.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(3):463-7. Abstract
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.  2015.  Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.. Clinical lung cancer. Abstract
Yuan Z, Baker K, Redman MW, Wang L, Adams SV, Yu M, Dickinson B, Makar K, Ulrich N, Böhm J et al..  2017.  Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.. British journal of cancer. Abstract
Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ et al..  2016.  Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA, Thompson IM.  2008.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.. Cancer prevention research (Philadelphia, Pa.). 1(3):174-81. Abstract
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S et al..  2008.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1):112-20. Abstract
Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ.  2012.  Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.. Cancer. Abstract
Misono S, Weiss NS, Fann JR, Redman MW, Yueh B.  2008.  Incidence of suicide in persons with cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4731-8. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD et al..  2015.  Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7):1514-24. Abstract
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA.  2015.  Lung-MAP-framework, overview, and design principles.. Chinese clinical oncology. 4(3):36. Abstract
Redman MW, Allegra CJ.  2015.  The Master Protocol Concept.. Seminars in oncology. 42(5):724-30. Abstract
Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH.  2013.  Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(10):2646-56. Abstract
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR et al..  2015.  Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(7):1099-106. Abstract
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R et al..  2014.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(11):1629-49. Abstract
Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM et al..  2010.  Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(22):3611-6. Abstract
Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ et al..  2014.  A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).. Cancer. Abstract
Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K.  2017.  Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman MW, Gandara DR.  2011.  Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(11):1938-45. Abstract